Topic: inter partes review
Biogen has been working hard to build out its pipeline, but as that effort plays out, the biotech faces a new patent challenge to its top moneymaker.
An appeals court rejected Allergan's attempt to protect Restasis patents with sovereign immunity, clearing the way for generics.
After a federal appeals court put Allergan's tribal licensing deal under review, judges scrutinized the arguments this week.
Dealing a blow to branded drugmakers, the U.S. Supreme Court found that inter partes review patent challenges are constitutional.
Allergan took all kinds of criticism for its tribal licensing deal, but an appeals court decision has breathed new life into the strategy.
After a Friday ruling, Allergan's eye drug Restasis has to face the very patent challenge the company sought to prevent.
Johnson & Johnson's prostate cancer drug Zytiga lost a key patent challenge that clears the way for cheap copycats later this year.
Allergan CEO Brent Saunders said it was "tenacity," not "desperation," that led the company to enter into the tribal licensing deal.
Allergan inked a settlement that gets one more would-be generic challenger off its radar, for now.
Eli Lilly has already foiled wannabe generic Alimta makers in court—and now it’s prevailed over one company taking the inter partes review route, too.